Lactose Intolerance Treatment Market Size to Hit USD 79.08 Billion by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Lactose Intolerance Treatment Market

5.1. COVID-19 Landscape: Lactose Intolerance Treatment Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Lactose Intolerance Treatment Market, By Treatment Type

8.1. Lactose Intolerance Treatment Market Revenue and Volume, by Treatment Type

8.1.1. Lactase Enzyme Supplements

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Probiotic Supplements

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Food & Beverages

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Pharmacological Therapies

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Others

8.1.5.1. Market Revenue and Volume Forecast

Chapter 9. Global Lactose Intolerance Treatment Market, By Formulation

9.1. Lactose Intolerance Treatment Market Revenue and Volume, by Formulation

9.1.1. Soild

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Liquid

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Semi-Solid

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Others

9.1.4.1. Market Revenue and Volume Forecast

Chapter 10. Global Lactose Intolerance Treatment Market, By Distribution Channel

10.1. Lactose Intolerance Treatment Market Revenue and Volume, by Distribution Channel

10.1.1. Pharmacy & Drug Stores

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Supermarkets & Hypermarkets

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Online Retailers

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Health & Specialty Stores

10.1.4.1. Market Revenue and Volume Forecast

10.1.5. Others (Direct-to-Consumer (DTC), Subscription Models)

10.1.5.1. Market Revenue and Volume Forecast

Chapter 11. Global Lactose Intolerance Treatment Market, By End User

11.1. Lactose Intolerance Treatment Market Revenue and Volume, by End User

11.1.1. Adults

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Children

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Infants

11.1.3.1. Market Revenue and Volume Forecast

Chapter 12. Global Lactose Intolerance Treatment Market, By Source of Enzyme (for enzyme-based therapies)

12.1. Lactose Intolerance Treatment Market Revenue and Volume, by Source of Enzyme (for enzyme-based therapies)

12.1.1. Fungal-derived Lactase

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Bacterial-derived Lactase

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Yeast-derived Lactase

12.1.3.1. Market Revenue and Volume Forecast

12.1.4. Others

12.1.4.1. Market Revenue and Volume Forecast

Chapter 13. Global Lactose Intolerance Treatment Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Treatment Type

13.1.2. Market Revenue and Volume Forecast, by Formulation

13.1.3. Market Revenue and Volume Forecast, by Distribution Channel

13.1.4. Market Revenue and Volume Forecast, by End User

13.1.5. Market Revenue and Volume Forecast, by Source of Enzyme (for enzyme-based therapies)

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Treatment Type

13.1.6.2. Market Revenue and Volume Forecast, by Formulation

13.1.6.3. Market Revenue and Volume Forecast, by Distribution Channel

13.1.6.4. Market Revenue and Volume Forecast, by End User

13.1.6.5. Market Revenue and Volume Forecast, by Source of Enzyme (for enzyme-based therapies)

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Treatment Type

13.1.7.2. Market Revenue and Volume Forecast, by Formulation

13.1.7.3. Market Revenue and Volume Forecast, by Distribution Channel

13.1.7.4. Market Revenue and Volume Forecast, by End User

13.1.7.5. Market Revenue and Volume Forecast, by Source of Enzyme (for enzyme-based therapies)

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Treatment Type

13.2.2. Market Revenue and Volume Forecast, by Formulation

13.2.3. Market Revenue and Volume Forecast, by Distribution Channel

13.2.4. Market Revenue and Volume Forecast, by End User

13.2.5. Market Revenue and Volume Forecast, by Source of Enzyme (for enzyme-based therapies)

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Treatment Type

13.2.6.2. Market Revenue and Volume Forecast, by Formulation

13.2.6.3. Market Revenue and Volume Forecast, by Distribution Channel

13.2.7. Market Revenue and Volume Forecast, by End User

13.2.8. Market Revenue and Volume Forecast, by Source of Enzyme (for enzyme-based therapies)

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Treatment Type

13.2.9.2. Market Revenue and Volume Forecast, by Formulation

13.2.9.3. Market Revenue and Volume Forecast, by Distribution Channel

13.2.10. Market Revenue and Volume Forecast, by End User

13.2.11. Market Revenue and Volume Forecast, by Source of Enzyme (for enzyme-based therapies)

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Treatment Type

13.2.12.2. Market Revenue and Volume Forecast, by Formulation

13.2.12.3. Market Revenue and Volume Forecast, by Distribution Channel

13.2.12.4. Market Revenue and Volume Forecast, by End User

13.2.13. Market Revenue and Volume Forecast, by Source of Enzyme (for enzyme-based therapies)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Treatment Type

13.2.14.2. Market Revenue and Volume Forecast, by Formulation

13.2.14.3. Market Revenue and Volume Forecast, by Distribution Channel

13.2.14.4. Market Revenue and Volume Forecast, by End User

13.2.15. Market Revenue and Volume Forecast, by Source of Enzyme (for enzyme-based therapies)

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Treatment Type

13.3.2. Market Revenue and Volume Forecast, by Formulation

13.3.3. Market Revenue and Volume Forecast, by Distribution Channel

13.3.4. Market Revenue and Volume Forecast, by End User

13.3.5. Market Revenue and Volume Forecast, by Source of Enzyme (for enzyme-based therapies)

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Treatment Type

13.3.6.2. Market Revenue and Volume Forecast, by Formulation

13.3.6.3. Market Revenue and Volume Forecast, by Distribution Channel

13.3.6.4. Market Revenue and Volume Forecast, by End User

13.3.7. Market Revenue and Volume Forecast, by Source of Enzyme (for enzyme-based therapies)

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Treatment Type

13.3.8.2. Market Revenue and Volume Forecast, by Formulation

13.3.8.3. Market Revenue and Volume Forecast, by Distribution Channel

13.3.8.4. Market Revenue and Volume Forecast, by End User

13.3.9. Market Revenue and Volume Forecast, by Source of Enzyme (for enzyme-based therapies)

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Treatment Type

13.3.10.2. Market Revenue and Volume Forecast, by Formulation

13.3.10.3. Market Revenue and Volume Forecast, by Distribution Channel

13.3.10.4. Market Revenue and Volume Forecast, by End User

13.3.10.5. Market Revenue and Volume Forecast, by Source of Enzyme (for enzyme-based therapies)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Treatment Type

13.3.11.2. Market Revenue and Volume Forecast, by Formulation

13.3.11.3. Market Revenue and Volume Forecast, by Distribution Channel

13.3.11.4. Market Revenue and Volume Forecast, by End User

13.3.11.5. Market Revenue and Volume Forecast, by Source of Enzyme (for enzyme-based therapies)

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Treatment Type

13.4.2. Market Revenue and Volume Forecast, by Formulation

13.4.3. Market Revenue and Volume Forecast, by Distribution Channel

13.4.4. Market Revenue and Volume Forecast, by End User

13.4.5. Market Revenue and Volume Forecast, by Source of Enzyme (for enzyme-based therapies)

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Treatment Type

13.4.6.2. Market Revenue and Volume Forecast, by Formulation

13.4.6.3. Market Revenue and Volume Forecast, by Distribution Channel

13.4.6.4. Market Revenue and Volume Forecast, by End User

13.4.7. Market Revenue and Volume Forecast, by Source of Enzyme (for enzyme-based therapies)

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Treatment Type

13.4.8.2. Market Revenue and Volume Forecast, by Formulation

13.4.8.3. Market Revenue and Volume Forecast, by Distribution Channel

13.4.8.4. Market Revenue and Volume Forecast, by End User

13.4.9. Market Revenue and Volume Forecast, by Source of Enzyme (for enzyme-based therapies)

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Treatment Type

13.4.10.2. Market Revenue and Volume Forecast, by Formulation

13.4.10.3. Market Revenue and Volume Forecast, by Distribution Channel

13.4.10.4. Market Revenue and Volume Forecast, by End User

13.4.10.5. Market Revenue and Volume Forecast, by Source of Enzyme (for enzyme-based therapies)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Treatment Type

13.4.11.2. Market Revenue and Volume Forecast, by Formulation

13.4.11.3. Market Revenue and Volume Forecast, by Distribution Channel

13.4.11.4. Market Revenue and Volume Forecast, by End User

13.4.11.5. Market Revenue and Volume Forecast, by Source of Enzyme (for enzyme-based therapies)

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Treatment Type

13.5.2. Market Revenue and Volume Forecast, by Formulation

13.5.3. Market Revenue and Volume Forecast, by Distribution Channel

13.5.4. Market Revenue and Volume Forecast, by End User

13.5.5. Market Revenue and Volume Forecast, by Source of Enzyme (for enzyme-based therapies)

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Treatment Type

13.5.6.2. Market Revenue and Volume Forecast, by Formulation

13.5.6.3. Market Revenue and Volume Forecast, by Distribution Channel

13.5.6.4. Market Revenue and Volume Forecast, by End User

13.5.7. Market Revenue and Volume Forecast, by Source of Enzyme (for enzyme-based therapies)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Treatment Type

13.5.8.2. Market Revenue and Volume Forecast, by Formulation

13.5.8.3. Market Revenue and Volume Forecast, by Distribution Channel

13.5.8.4. Market Revenue and Volume Forecast, by End User

13.5.8.5. Market Revenue and Volume Forecast, by Source of Enzyme (for enzyme-based therapies)

Chapter 14. Company Profiles

14.1. Johnson & Johnson (Lactaid)

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Danone S.A.

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. NOW Health Group, Inc.

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Danone S.A.

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Novozymes A/S

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Arla Foods

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. BioGaia AB

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Ganeden Inc. (Part of Kerry Group)

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Vitacost (Kroger Co.)

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Schiff Vitamins (Reckitt Benckiser Group)

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The lactose intolerance treatment market size is expected to increase from USD 33.9 billion in 2024 to USD 79.08 billion by 2034.

The lactose intolerance treatment market is expected to grow at a compound annual growth rate (CAGR) of around 8.84% from 2025 to 2034.

The major players in the lactose intolerance treatment market include Nestlé Health Science Johnson & Johnson (Lactaid), Danone S.A., NOW Health Group, Inc., Garden of Life, Chr. Hansen Holding A/S, Nature’s Way Products, LLC, GlaxoSmithKline plc, Novozymes A/S, Arla Foods, Valio Ltd., Enzymedica, Inc., Deerland Probiotics & Enzymes, Puritan’s Pride, Lifeway Foods, Inc., Amway (Nutrilite), BioGaia AB, Ganeden Inc. (Part of Kerry Group), Vitacost (Kroger Co.), and Schiff Vitamins (Reckitt Benckiser Group).

The driving factors of the lactose intolerance treatment market are the rising number of cases of lactose intolerance worldwide is a significant factor driving the growth of the market

North America region will lead the global lactose intolerance treatment market during the forecast period 2025 to 2034.